An Open-label, Single Arm Study to Provide Additional Information on Safety and Effectiveness of rVSVΔG-ZEBOV-GP

Trial Profile

An Open-label, Single Arm Study to Provide Additional Information on Safety and Effectiveness of rVSVΔG-ZEBOV-GP

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2018

At a glance

  • Drugs RVSV-S-GP/VP40 vaccine (Primary)
  • Indications Ebola virus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Jul 2018 Planned End Date changed from 31 Dec 2019 to 31 Aug 2018.
    • 18 Jul 2018 Status changed from suspended to active, no longer recruiting.
    • 01 Feb 2018 Planned End Date changed from 31 Mar 2018 to 31 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top